29346-51-8 Usage
Urea derivative
A compound derived from urea a molecule that contains two nitrogen atoms bonded to carbon atoms.
Functional groups
Contains an ethyl group (C2H5) and a hydroxyethyl group (C2H4OH) attached to the nitrogen atoms of the urea molecule.
Polar substance
Possesses a dipole moment due to the presence of polar functional groups, making it more attracted to polar molecules and solvents.
Water-soluble
Easily dissolves in water due to its polar nature and the presence of hydrophilic functional groups.
Common use in cosmetics
Widely used in skincare products as a moisturizing agent.
Moisturizing properties
Enhances the skin's moisture retention by forming a protective layer and attracting water molecules.
Potential applications in drug delivery
Being studied for its possible use in pharmaceutical formulations and drug delivery systems due to its unique properties.
Hydroxyethyl group
A hydrophilic functional group (C2H4OH) that contributes to the compound's water solubility and moisturizing properties.
Check Digit Verification of cas no
The CAS Registry Mumber 29346-51-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,3,4 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 29346-51:
(7*2)+(6*9)+(5*3)+(4*4)+(3*6)+(2*5)+(1*1)=128
128 % 10 = 8
So 29346-51-8 is a valid CAS Registry Number.
29346-51-8Relevant articles and documents
ADENOSINE RECEPTOR BINDING COMPOUNDS
-
Paragraph 00356, (2020/02/06)
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.
FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
-
Paragraph 0487, (2017/01/31)
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
